On Tuesday, Alzamend Neuro Inc ALZN mentioned it completed analyzing the ultimate full knowledge set from a nonclinical examine evaluating mind and plasma lithium exposures between AL001 and lithium carbonate in Alzheimer’s transgenic mice.
The examine concerned administering AL001 to 5XFAD mice, a acknowledged mannequin for Alzheimer’s analysis, to match its results in opposition to lithium carbonate, an FDA-approved and marketed API.
Additionally Learn: EXCLUSIVE: Alzamend Neuro To Assess AL001 Alzheimer’s Candidate In opposition to Generally Marketed Lithium Salt In Section 2 Head-To-Head Examine
Mice acquired excessive or low doses scaled to people of AL001 and lithium carbonate over 14 days to watch pharmacokinetic steady-state drug situations.
Key Findings:
- Each therapies didn’t negatively impression the mice’s physique weight or scientific indicators through the therapy interval.
- AL001 confirmed decrease plasma lithium ranges than lithium carbonate, lowering the danger of adversarial systemic results and suggesting an enlargement for the protection of lithium’s therapeutic index.
- AL001 confirmed larger lithium concentrations in mind tissues than lithium carbonate, notably at decrease doses.
- The examine discovered that totally different mind areas soak up and retain lithium otherwise. This implies therapies can doubtlessly be tailor-made to focus on particular mind areas.
The corporate says that the outcomes spotlight the potential scientific benefits of AL001 for situations like Alzheimer’s, bipolar dysfunction, main depressive dysfunction, and post-traumatic stress dysfunction at low doses.
By lowering the systemic burden, AL001 might reduce the danger of unintended effects similar to thyroid and kidney problems typically related to extant lithium therapies, positioning AL001 as a candidate for safer long-term therapy choices with out the necessity for routine blood lithium monitoring.
In October, Alzamend Neuro acquired the ultimate full knowledge set from its a number of ascending dose scientific trial for AL001 for dementia associated to Alzheimer’s. Preliminary outcomes have been launched in June 2023.
Worth Motion: ALZN inventory is up 6.67% at $1.44 through the premarket session eventually examine Tuesday.
Learn Subsequent:
Market Information and Information dropped at you by Benzinga APIs
© 2024 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
